Clinical Research Studies

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Obesity
  Cv Disease
• Age: Between 45 years - 100 years
• Gender: Male or Female

• Other Inclusion Criteria:
  

  1. Subjects who are capable of giving informed consent in English
  2. Subjects who are at least 45 years old
  3. Subjects with a BMI > 27kg/m2 at the time of enrollment.
  4. Have established CV disease as evidenced by at least one of the following:
     • prior myocardial infarction
     • prior stroke (ischemic or hemorrhagic stroke)
     • symptomatic peripheral arterial disease (PAD), as evidenced by intermittent claudication with ankle-brachial index (ABI) < 0.85 (at rest), or peripheral arterial revascularization procedure, or amputation due to atherosclerotic disease

  
  

You may not be eligible for this study if the following are true:

• Cardiovascular-related:

  1. Subjects who have any of the following: myocardial infarction, stroke, hospitalization for unstable angina pectoris or transient ischemic attack within the past 60 days prior to the day of screening
  2. Subjects who have planned coronary, carotid or peripheral artery revascularization known on the day of screening
  3. Subjects who have presently classified as being in New York Heart Association (NYHA) Class IV heart failure

  Glycaemia-related:

  1. Subjects who have HbA1c = 48 mmol/mol (6.5 %) as measured by the central laboratory at screening
  2. Subjects who have History of type 1 or type 2 diabetes (history of gestational diabetes is allowed)
  3. Subjects who have treatment with glucose-lowering agent(s) within 90 days before screening
  4. Subjects who have treatment with any GLP-1 RA within 90 days before screening

  General safety:

  1. Subjects who have history or presence of chronic pancreatitis
  2. Subjects who have the presence of acute pancreatitis within the past 180 days prior to the day of screening
  3. Subjects who have personal or first degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma
  4. Subjects who have end stage renal disease or chronic or intermittent hemodialysis or peritoneal dialysis
  5. Subjects who have presence or history of malignant neoplasms within the past 5 years prior to the day of screening Basal and squamous cell skin cancer and any carcinoma in-situ are allowed
  6. Subjects with severe psychiatric disorder
  7. Subjects with known or suspected hypersensitivity to trial product(s) or related products
  8. Subjects who participated in this trial previously
  9. Subjects who received any investigational medicinal product within 30 days before screening
  10. Subjects who are pregnant, breastfeeding or intends to become pregnant or is of child bearing potential and not using a highly effective contraceptive method.
  11. Subjects who have any disorder, unwillingness or inability, which in the investigator's opinion, might jeopardize the subject's safety or compliance with the protocol